INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 50 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $10,031,000 | -17.2% | 12,400,000 | -22.5% | 0.01% | -26.3% |
| Q2 2020 | $12,120,000 | +23.8% | 16,000,000 | +34.9% | 0.02% | +5.6% |
| Q1 2020 | $9,788,000 | +41.8% | 11,864,000 | +73.8% | 0.02% | +80.0% |
| Q4 2019 | $6,901,000 | -45.0% | 6,828,000 | -51.2% | 0.01% | -50.0% |
| Q2 2019 | $12,552,000 | +9.7% | 14,000,000 | +21.7% | 0.02% | +5.3% |
| Q1 2019 | $11,437,000 | +194.2% | 11,500,000 | +130.0% | 0.02% | +171.4% |
| Q3 2017 | $3,887,000 | -68.2% | 5,000,000 | -60.0% | 0.01% | -69.6% |
| Q2 2017 | $12,218,000 | +30.4% | 12,500,000 | +25.0% | 0.02% | +27.8% |
| Q1 2017 | $9,368,000 | -9.3% | 10,000,000 | -13.2% | 0.02% | -14.3% |
| Q4 2016 | $10,329,000 | -44.3% | 11,525,000 | -30.2% | 0.02% | -43.2% |
| Q3 2016 | $18,531,000 | – | 16,500,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 12,851,000 | $12,016,000 | 2.95% |
| Context Capital Management, LLC | 3,000,000 | $2,804,000 | 2.24% |
| Man Investments (CH) AG | 3,000,000 | $2,798,000 | 1.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,500,000 | $39,540,000 | 1.52% |
| MACKAY SHIELDS LLC | 17,069,000 | $15,982,000 | 0.73% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 73,035,000 | $68,425,000 | 0.63% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,307,000 | $39,554,000 | 0.61% |
| LINDEN ADVISORS LP | 14,122,000 | $13,194,000 | 0.49% |
| GLG LLC | 9,100,000 | $8,486,000 | 0.47% |
| Jabre Capital Partners S.A. | 3,400,000 | $3,179,000 | 0.38% |